Odyssey Therapeutics
Odyssey Therapeutics is a clinical-stage biopharmaceutical company developing precision medicines for patients with autoimmune and inflammatory diseases, and cancer. Founded by Gary Glick, David Pompliano, Eicke Latz, Felix Meissner, Florian Schmidt, and Kim Lewis, the company leverages immunobiology and drug discovery to target upstream signaling nodes in immune-mediated diseases. Lead programs include OD-001 (RIPK2 inhibitor in Phase 2 trials for ulcerative colitis) and OD-07656, with additional candidates targeting SLC15A4 and other mechanisms. OD-001 has demonstrated proof-of-concept in Phase 2a trials for moderate-to-severe ulcerative colitis and is advancing toward Phase 2b monotherapy and Phase 2a combination studies.
Public Company
Odyssey Therapeutics is publicly traded
This company is no longer available on our private secondary market. Shares can be traded publicly under its listed ticker.
Overview
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2021
Employees
51–200
Total Funding
$1.06B
5 rounds
Secondary Signals
2 signalsPriced upsized IPO at $18.00/share, ~$304M gross proceeds, began trading on Nasdaq as ODTX
Public listing converts pre-IPO holders' stakes to tradeable public equity, ending private secondary interest
Closed oversubscribed $213M Series D with new investors TPG, Lightspeed, Jeito, Dimension, Affinity, Wedbush
Fresh primary capital ahead of IPO push signals strong late-stage investor demand
Funding
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Total raised $1.06B across 5 rounds
Last updated 08-11-2026
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| 2026 | IPO | $304M | — | |
| Sep 10, 2025 | Series D Press release | $213M | — | Not disclosed |
| Dec 5, 2023 | Series C Press release | $101M | — | Ascenta Capital |
Leadership
Gary D. Glick
Founder, President & CEO
David Pompliano
Co-Founder & Chief Innovation Officer
Eicke Latz
Co-Founder
Felix Meissner
Co-Founder
Florian Schmidt
Co-Founder
Kim Lewis
Co-Founder
Competitors
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Revolution Medicines
Clinical-stage biopharmaceutical company developing targeted therapies for cancer and autoimmune disease
Lodo Therapeutics
Biopharmaceutical company developing therapies for immune-mediated diseases
IFM Therapeutics
Biopharmaceutical company developing innate immune system modulators for inflammatory and autoimmune diseases
Odyssey Therapeutics Investment FAQ
Odyssey Therapeutics FAQ
Odyssey Therapeutics completed its IPO on May 8, 2026, listing on the Nasdaq Capital Market under the ticker ODTX. The upsized offering of 15,500,000 shares priced at $18.00 per share on May 7 — the top of the $16-$18 range and well above the 13.2 million shares originally proposed — generating roughly $304 million in gross proceeds together with a concurrent private placement of 1,388,889 shares to a TPG Life Sciences Innovations affiliate; underwriters received a 30-day option on a further 2,325,000 shares and the offering closed on or about May 11, 2026. J.P. Morgan, TD Cowen and Cantor were joint bookrunners, with Wedbush PacGrow and Oppenheimer as co-lead managers. This was the company's second attempt after withdrawing a 2025 filing; proceeds fund OD-001 (RIPK2 inhibitor) through Phase 2b monotherapy and Phase 2a combination trials.
Odyssey Therapeutics shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker to place an order.
Odyssey Therapeutics raised $1.06B across 5 disclosed funding rounds prior to its public listing.
Odyssey Therapeutics was co-founded by Gary D. Glick, David Pompliano, Eicke Latz, and 3 others in 2021.
Odyssey Therapeutics is headquartered in Boston, Massachusetts.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.